Core Safety Profile. Date of FAR:
|
|
- Elizabeth Tate
- 6 years ago
- Views:
Transcription
1 Core Safety Profile Active substance: Bisoprolol + Hydrochlorothiazide Pharmaceutical form(s)/strength: Film-coated tablet: 2.5 mg / 6.25 mg, 5 mg / 6.25 mg, 10 mg / 6.25 mg, 5 mg / 12.5 mg, 10 mg / 25 mg; Strengths 5 mg / 12.5 mg and 10 mg / 25 mg are not registered in the P-RMS P - RMS: FR/H/PSUR/0031/001 Date of FAR:
2 * This document aims to support the complex actual CSI situation of the bisoprolol and hydrochlorothiazide combiation products. It contains the Core Safety Information as the MAH anticipates to be reflected in the future agreed Core Safety Profile. It is based on Annex 1, includes the content of Annex 2 and reflects the wording of the intended variation to remove the statement on mild to moderate impairment of liver function in the dosage and administration section. This potential EU Core Safety Profile (CSP) is presented in QRD format containing the complete Core Safety Information of CSDS 3.0 provided with the PSUR. Editorial remarks Please note that the text in italics identifies only notes for correct implementation of the respective information; it is not intended to appear in any derived national product information. All core safety statements mentioned in the CSP do not refer to a specific tradename. In place of the tradename, the following code is used throughout the document: {Tradename} represents the local product name of any formulation. {Tradename 5/12.5} represents the local tradename and strength of the combination containing 5 mg bisoprolol and 12.5 mg hydrochlorothiazide. {Tradename 10/25} represents the local tradename and strength of the combination containing 10 mg bisoprolol and 25 mg hydrochlorothiazide. {Tradename 2.5/6.25} represents the local tradename and strength of the combination containing 2.5 mg bisoprolol and 6.25 mg hydrochlorothiazide. {Tradename 5/6.25} represents the local tradename and strength of the combination containing 5 mg bisoprolol and 6.25 mg hydrochlorothiazide. {Tradename 10/6.25} represents the local tradename and strength of the combination containing 10 mg bisoprolol and 6.25 mg hydrochlorothiazide. 2/11
3 4.2 Posology and method of administration The safety information presented in this document refers to the instructions for use according national Marketing Authorisation. Administration Special Populations Renal or hepatic impairment applies only to {Tradename 5/12.5, 10/25} In mild-to-moderate impairment of kidney or liver function the elimination of the HCTZ component of {Tradename} 5 mg/12.5 mg and 10 mg/25 mg is reduced, so that preference may have to be given to the lower dose form ({Tradename} 5 mg/12.5 mg). Paediatric patients There is no paediatric experience with {Tradename}, therefore its use cannot be recommended for children. 4.3 Contraindications {Tradename} is contra-indicated in patients with hypersensitivity to bisoprolol, hydrochlorothiazide, other thiazides, sulphonamides, or any of the excipients acute heart failure or during episodes of heart failure decompensation requiring intravenous inotropic therapy cardiogenic shock second or third degree AV block sick sinus syndrome sinoatrial block symptomatic bradycardia severe bronchial asthma or severe chronic obstructive pulmonary disease severe forms of peripheral arterial occlusive disease or severe forms of Raynaud's syndrome untreated phaeochromocytoma severe renal impairment (creatinine clearance 30 ml/min) 3/11
4 severe hepatic impairment metabolic acidosis refractory hypokalaemia applies only to {Tradename 5/12.5, 10/25} lactation severe hyponatraemia hypercalcaemia gout 4.4 Special warnings and precautions for use Treatment with bisoprolol must not be withdrawn abruptly unless clearly indicated, since abrupt withdrawal of bisoprolol may lead to an acute deterioration of the patient's condition in particular in patients with ischaemic heart disease. {Tradename} must be used with caution in patients with accompanying heart failure diabetes mellitus showing large fluctuations in blood glucose values; symptoms of hypoglycaemia can be masked strict fasting first degree AV block Prinzmetal's angina peripheral arterial occlusive disease. Aggravation of symptoms may occur especially when starting therapy hypovolaemia impaired liver function As with other beta-blockers, bisoprolol may increase both the sensitivity towards allergens and the severity of anaphylactic reactions. This also applies to desensitisation therapy. Epinephrine treatment may not always yield the expected therapeutic effect. Patients with psoriasis or with a history of psoriasis should only be given beta-blockers (e.g. bisoprolol) after carefully balancing of benefits against risks. The symptoms of thyrotoxicosis may be masked under treatment with bisoprolol. 4/11
5 In patients with phaeochromocytoma bisoprolol must not be administered until after alphareceptor blockade. In patients undergoing general anaesthesia. The anaesthetist must be aware of betablockade. If it is thought necessary to withdraw beta-blocker therapy before surgery, this should be done gradually and completed about 48 hours before anaesthesia. In bronchial asthma or other chronic obstructive pulmonary diseases, which may cause symptoms, concomitant bronchodilating therapy is recommended. Occasionally an increase of the airway resistance may occur in patients with asthma, therefore the dose of beta2-stimulants may have to be increased. If photosensitivity reactions occur, it is recommended to protect exposed areas to the sun or to artificial UVA light. In severe cases it may be necessary to stop the treatment. Long-term, continuous administration of hydrochlorothiazide may lead to fluid and electrolyte disturbances, in particular to hypokalaemia and hyponatraemia, also to hypomagnesaemia and hypochloraemia, and hypercalcaemia. Hypokalaemia facilitates the development of severe arrhythmias, particularly torsade de pointes, which may be fatal. During long term-therapy with {Tradename}, monitoring of serum electrolytes (especially potassium, sodium, calcium), creatinine and urea, the serum lipids (cholesterol and triglycerides), uric acid as well as blood glucose is recommended. In patients with hyperuricaemia the risk for attacks of gout may be increased. 4.5 Interaction with other medicinal products and other forms of interaction Combinations not recommended Lithium: {Tradename} may intensify the cardiotoxic and neurotoxic effect of lithium through a reduction of lithium excretion. Calcium antagonists of the verapamil type and the diltiazem type: Negative effect on contractility and atrio-ventricular conduction. Intravenous administration of verapamil in patients on ß-blocker treatment may lead to profound hypotension and atrioventricular block. Centrally-acting antihypertensive agents: Concomitant use of centrally-acting antihypertensive agents may lead to a further reduction in heart rate and cardiac output 5/11
6 and to vasodilatation. Abrupt withdrawal, may increase the risk of 'rebound hypertension'. Combinations to be used with caution Calcium antagonists of the dihydropyridine type: Concomitant use may increase the risk of hypotension, and an increase in the risk of a further deterioration of the ventricular pump function in patients with heart failure cannot be excluded. Concomitant use with other antihypertensive agents or with other medicinal products with blood pressure lowering potential may increase the risk of hypotension. ACE inhibitors, Angiotensin II antagonists: Risk of significant fall in blood pressure and/or acute renal failure during initiation of ACE inhibitor therapy in patients with preexisting sodium depletion (particularly in patients with renal artery stenosis). If prior diuretic therapy has produced sodium depletion, either stop the diuretic 3 days before starting ACE inhibitor therapy, or initiate ACE inhibitor therapy at a low dose. Class-I antiarrhythmic agents: Effect on atrio-ventricular conduction time may be potentiated and negative inotropic effect increased. Class-III antiarrhythmic agents: Effect on atrio-ventricular conduction time may be potentiated. Antiarrhythmic agents that may induce torsade de pointes: Hypokalaemia may facilitate the occurrence of torsades de pointes. Nonantiarrhythmic agents that may induce torsade de pointes: Hypokalaemia may facilitate the occurrence of torsades de pointes. Parasympathomimetic agents: Concomitant use may increase atrio-ventricular conduction time and the risk of bradycardia. Topical beta-blockers (e.g. eye drops for glaucoma treatment) may add to the systemic effects of bisoprolol. Insulin and oral antidiabetic agents: Increase of blood sugar lowering effect. Blockade of beta-adrenoceptors may mask symptoms of hypoglycaemia. Anaesthetic agents: Attenuation of the reflex tachycardia and increase of the risk of hypotension. Digitalis glycosides: Increase of atrio-ventricular conduction time, reduction in heart rate. If hypokalaemia and/or hypomagnesaemia develop during treatment with {Tradename} the myocardium may show increased sensitivity to cardiac glycosides, leading to an enhanced effect and adverse effects of the glycosides. 6/11
7 Non-steroidal anti-inflammatory drugs (NSAIDs): NSAIDs may reduce the hypotensive effect. In patients developing hypovolaemia the concomitant administration of NSAIDs can trigger acute renal failure. Beta-sympathomimetics: Combination with bisoprolol may reduce the effect of both agents. Sympathomimetics that activate both beta- and alpha-adrenoceptors: Combination with bisoprolol may lead to blood pressure increase. Such interactions are considered to be more likely with nonselective beta-blockers. Potassium-wasting medicinal products may result in increased potassium losses. Methyldopa: haemolysis due to the formation of antibodies to hydrochlorothiazide has been described in isolated cases. The effect of uric-acid-lowering agents may be attenuated in concomitant administration of {Tradename}. Cholestyramine, colestipol: reduces the absorption of the hydrochlorothiazide component of {Tradename}. Combinations to be considered Mefloquine: increased risk of bradycardia. Corticosteroids: Reduced antihypertensive effect. 4.6 Pregnancy and lactation Pregnancy For all strengths (2.5/6.25, 5/6.25, 10/6.25, 5/12.5 and 10/25): Bisoprolol Bisoprolol has pharmacological effects that may cause harmful effects on pregnancy and/or the foetus/newborn. In general, beta-adrenoceptor blockers reduce placental perfusion, which has been associated with growth retardation, intrauterine death, abortion or early labour. Adverse effects (e.g. hypoglycaemia and bradycardia) may occur in the foetus and newborn infant. If treatment with beta-adrenoceptor blockers is necessary, beta1-selective adrenoceptor blockers are preferable. Hydrochlorothiazide 7/11
8 There is limited experience with hydrochlorothiazide during pregnancy, especially during the first trimester. Animal studies are insufficient. Hydrochlorothiazide crosses the placenta. Based on the pharmacological mechanism of action of hydrochlorothiazide its use during the second and third trimester may compromise foeto-placental perfusion and may cause foetal and neonatal effects like icterus, disturbance of electrolyte balance and thrombocytopenia. Hydrochlorothiazide should not be used for gestational oedema, gestational hypertension or preeclampsia due to the risk of decreased plasma volume and placental hypoperfusion, without a beneficial effect on the course of the disease. Hydrochlorothiazide should not be used for essential hypertension in pregnant women except in rare situations where no other treatment could be used. Lactation applies only to {Tradename 5/12.5, 10/25}: {Tradename}must not be used in breastfeeding women. Hydrochlorothiazide can inhibit the milk production. applies only to {Tradename 2.5/6.25, 5/6.25, 10/6.25} {Tradename} is not recommended in breastfeeding women. Hydrochlorothiazide can inhibit the milk production. 4.7 Effects on ability to drive and use machines In general {Tradename} has no or neglible influence on the ability to drive and use machines. However, depending on the individual patients response to treatment the ability to drive a vehicle or to use machines may be impaired. This needs to be considered particularly at start of treatment, upon change of medication, or in conjunction with alcohol. 4.8 Undesirable effects Common ( 1% and < 10%), uncommon ( 0.1% and < 1%), rare ( 0.01% and < 0.1%), very rare (< 0.01%) including isolated cases. Blood and lymphatic system disorders 8/11
9 Rare: leucopenia, thrombocytopenia Very rare: agranulocytosis Metabolism and nutrition disorders Uncommon: loss of appetite Very rare: metabolic alkalosis applies only to {Tradename 5/12.5, 10/25} Common: hyperglycaemia, hyperuricaemia, disturbances of fluid and electrolyte balance (in particular hypokalaemia and hyponatraemia, also hypomagnesaemia and hypochloraemia as well as hypercalcaemia) applies only to {Tradename 2.5/6.25, 5/6.25, 10/6.25} Uncommon: hyperglycaemia, hyperuricaemia, disturbances of fluid and electrolyte balance (in particular hypokalaemia and hyponatraemia, also hypomagnesaemia and hypochloraemia as well as hypercalcaemia) Psychiatric disorders Uncommon: depression, sleep disorders Rare: nightmares, hallucinations Nervous system disorders Common: dizziness*, headache* Eye disorders Rare: reduced tear flow (to be taken into consideration in patients wearing contact lenses), visual disturbances Very rare: conjunctivitis Ear and labyrinth disorders Rare: hearing disorders Cardiac disorders Uncommon: bradycardia, AV-conduction disturbances, worsening of pre-existing heart failure Vascular disorders Common: feeling of coldness or numbness in extremities Uncommon: orthostatic hypotension Respiratory, thoracic and mediastinal disorders Uncommon: bronchospasm in patients with bronchial asthma or history of obstructive airways disease Rare: allergic rhinitis 9/11
10 Gastrointestinal disorders Common: gastrointestinal complaints such as nausea, vomiting, diarrhoea, constipation Uncommon: abdominal complaints applies only to {Tradename 5/12.5, 10/25} Uncommon: pancreatitis applies only to {Tradename 2.5/6.25, 5/6.25, 10/6.25} Very rare: pancreatitis Hepatobilary disorders Rare: hepatitis, jaundice Skin and subcutaneous tissue disorders Rare: hypersensitivity reactions such as itching, flush, rash, photodermatitis, purpura, urticaria Very rare: alopecia, cutaneous lupus erythematosus. Beta-blockers may provoke or worsen psoriasis or induce psoriasis-like rash. Musculoskeletal and connective tissue disorders Uncommon: muscle weakness, muscle cramps Reproductive system and breast disorders Rare: potency disorders General disorders Common: fatigue* Uncommon: asthenia Very rare: chest pain Investigations: Uncommon: increase in amylase, reversible increase of serum creatinine and urea Rare: increase in liver enzymes (ASAT, ALAT) applies only to {Tradename 2.5/6.25, 5/6.25, 10/6.25} Uncommon: increased triglyceride and cholesterol levels, glucosuria applies only to {Tradename 5/12.5, 10/25} Common: increased triglyceride and cholesterol levels, glucosuria *These symptoms occur in particular at the start of treatment. They are generally mild and mostly disappear within 1-2 weeks. 10/11
11 4.9 Overdose Symptoms The most common signs expected with overdose of a beta-blocker are bradycardia, hypotension, bronchospasm, acute cardiac insufficiency and hypoglycaemia. There is a wide inter-individual variation in sensitivity to one single high dose of bisoprolol and patients with heart failure are probably very sensitive. The clinical picture in acute or chronic overdose of hydrochlorothiazide is characterised by the extent of fluid and electrolyte loss. Most common signs are dizziness, nausea, somnolence, hypovolaemia, hypotension, hypokalaemia. Management In general, if overdose occurs, discontinuation of {Tradename} and supportive and symptomatic treatment is recommended. Limited data suggest that bisoprolol is hardly dialysable. The degree to which hydrochlorothiazide is removed by haemodialysis has not been established. 11/11
Core Safety Profile. Pharmaceutical form(s)/strength: Film-coated tablets 1.25 mg, 2.5 mg, 3.75 mg, 5 mg, 7.5 mg and 10 mg. Date of FAR:
Core Safety Profile Active substance: Bisoprolol Pharmaceutical form(s)/strength: Film-coated tablets 1.25 mg, 2.5 mg, 3.75 mg, 5 mg, 7.5 mg and 10 mg P - RMS: FI/H/PSUR/0002/002 Date of FAR: 13.12.2011
More informationDistribution Bisoprolol is about 30% bound to plasma proteins. Bisoprolol is moderately lipid-soluble.
PACKAGE INSERT TEMPLATE FOR BISOPROLOL TABLET Brand or Product Name [Product name] Tablet 2.5mg [Product name] Tablet 5mg [Product name] Tablet 10mg Name and Strength of Active Substance(s) Bisoprolol
More informationCore Safety Profile. Pharmaceutical form(s)/strength: Sterile eye drops 1%, 2% Date of FAR:
Core Safety Profile Active substance: Carteolol Pharmaceutical form(s)/strength: Sterile eye drops 1%, 2% P - RMS: SK/H/PSUR/0002/002 Date of FAR: 16.03.2012 4.1 THERAPEUTIC INDICATIONS Ocular hypertension
More informationBisoprolol Fumarate 2.5 mg, 5 mg and 10 mg Tablet
Bisoprolol Fumarate 2.5 mg, 5 mg and 10 mg Tablet Description Betapro is a preparation of Bisoprolol Fumarate. Bisoprolol is used alone or in combination with other medications to treat high blood pressure.
More informationPharmaceutical form(s)/strength: Solution: 5 mg/ml Suspensions: 2.5 and 5 mg/ml P-RMS:
0BCore Safety Profile Active substance: Betaxolol eyedrops Pharmaceutical form(s)/strength: Solution: 5 mg/ml Suspensions: 2.5 and 5 mg/ml P-RMS: HU/H/PSUR/0010/002 Date of FAR: 20.03.2013 4.2 Posology
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Bisoprolol fumaraat BP 10mg tabletten 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 10mg of bisoprolol fumarate Excipients:
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Concor 5 mg film-coated tablets Concor 10 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Concor 5 mg : Each tablet
More informationAngina pectoris due to coronary atherosclerosis : Atenolol is indicated for the long term management of patients with angina pectoris.
Lonet Tablet Description Lonet contains Atenolol, a synthetic β1 selective (cardioselective) adrenoreceptor blocking agent without membrane stabilising or intrinsic sympathomimetic (partial agonist) activity.
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Tablets containing 100 mg of Atenolol Ph. Eur. and 25 mg of Chlortalidone Ph.Eur. For excipients, see Section 6.
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Tenoretic 100 mg/25 mg film coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Tablets containing 100 mg of Atenolol Ph. Eur.
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF MEDICINAL PRODUCT ATENIGRON 100-mg + 25-mg Tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: Active ingredients: Atenolol 100 mg Chlorthalidone
More informationNEW ZEALAND DATA SHEET
1 PRODUCT NAME Bisoprolol 2.5 mg film coated tablet Bisoprolol 5 mg film coated tablet Bisoprolol 10 mg film coated tablet 2 QUALITATIVE AND QUANTITATIVE COMPOSITION For 2.5mg: Each film-coated tablet
More informationCommon Technical Document Bisoprolol hemifumarate 5 mg tablets. Bisoprololfumaraat 5 mg, film-coated tablets
Labelling and Package Leaflet page 1/11 1.3.5 SUMMARY OF PRODUCT CHARACTERISTICS 1 Name of the medicinal product Bisoprololfumaraat 5 mg, film-coated 2 Qualitative and quantitative composition Each tablet
More information0BCore Safety Profile. Pharmaceutical form(s)/strength: Film-coated tablet 40, 80, 160, 320 mg SE/H/PSUR/0024/003 Date of FAR:
0BCore Safety Profile Active substance: Valsartan Pharmaceutical form(s)/strength: Film-coated tablet 40, 80, 160, 320 mg P-RMS: SE/H/PSUR/0024/003 Date of FAR: 28.02.2013 4.2 Posology and method of administration
More informationP-RMS: FR/H/PSUR/0056/001
Core Safety Profile Active substance: Piretanide Pharmaceutical form(s)/strength: Tablets, 3mg, 6mg Capsules, 6mg Ampoules, 6mg, 12mg, 60mg P-RMS: FR/H/PSUR/0056/001 Date of FAR: 21.12.2009 4.2 Posology
More informationByol HL 5mg/12.5mg Film-coated Tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER Byol HL 5mg/12.5mg Film-coated Tablets BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE This leaflet is a copy of the Summary of Product Characteristics and Patient
More informationSummary of Product Characteristics
Summary of Product Characteristics 1. NAME OF THE MEDICINAL PRODUCT Bisoprolol fumarate Actavis 5 mg, tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet Bisoprolol fumarate Actavis 5 mg contains
More informationZAROXOLYN 5mg tablets ZAROXOLYN 10 mg tablets Metolazone. PHARMACOTHERAPEUTIC CATEGORY Diuretic with minor diuretic action, non-associated.
ZAROXOLYN 5mg tablets ZAROXOLYN 10 mg tablets Metolazone PHARMACOTHERAPEUTIC CATEGORY Diuretic with minor diuretic action, non-associated. THERAPEUTIC INDICATIONS Zaroxolyn is indicated in the treatment
More informationpale yellow, heart-shaped, scored and film-coated tablets pale orange - light orange, heart-shaped, scored and film-coated tablets
1. NAME OF THE MEDICINAL PRODUCT Cardicor 1.25 mg film-coated tablets Cardicor 2.5 mg film-coated tablets Cardicor 3.75 mg film-coated tablets Cardicor 5 mg film-coated tablets Cardicor 7.5 mg film-coated
More informationCore Safety Profile. Pharmaceutical form(s)/strength: Immediate release tablets 1 mg, 2 mg, 4 mg and 8 mg (IR) Date of FAR:
Core Safety Profile Active substance: Doxazosin Pharmaceutical form(s)/strength: Immediate release tablets 1 mg, 2 mg, 4 mg and 8 mg (IR) P - RMS: DK/H/PSUR/0004/002 Date of FAR: 12.12.2011 4.3 Contraindications
More informationPACKAGE INSERT TEMPLATE FOR SALBUTAMOL TABLET & SALBUTAMOL SYRUP
PACKAGE INSERT TEMPLATE FOR SALBUTAMOL TABLET & SALBUTAMOL SYRUP Brand or Product Name [Product name] Tablet 2mg [Product name] Tablet 4mg [Product name] Syrup 2mg/5ml Name and Strength of Active Substance(s)
More informationAdrenergic Receptor as part of ANS
Adrenergic Receptor as part of ANS Actions of Adrenoceptors Beta-1 adrenergic receptor Located on the myocytes of the heart Specific actions of the β1 receptor include: 0 Increase cardiac output, by 0
More informationTENORMIN 25 mg, 50 mg and 100 mg Tablet ASTRAZENECA
10-14 TENORMIN 25 mg, 50 mg and 100 mg Tablet ASTRAZENECA Atenolol Film-coated tablets and solution for injection Composition Tablets containing 25 mg, 50 mg or 100 mg of Atenolol Ph. Eur. Injection for
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Bisoprolol fumarate 10 mg Film-coated Tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each Film-coated Tablet contains 10 mg of bisoprolol
More informationMETOTRUST XL-25/50 Metoprolol Succinate Extended-Release Tablets
METOTRUST XL-25/50 Metoprolol Succinate Extended-Release Tablets COMPOSITION Each film-coated tablet of Metotrust XL-25 contains: Metoprolol Succinate USP 23.75 mg equivalent to Metoprolol Tartrate 25
More informationNew Zealand Data Sheet. Arrow-Bendrofluazide Bendroflumethiazide (also known as Bendrofluazide) Tablets 2.5mg and 5mg
New Zealand Data Sheet Arrow-Bendrofluazide Bendroflumethiazide (also known as Bendrofluazide) Tablets 2.5mg and 5mg Description Arrow-Bendrofluazide Tablets contain 2.5 and 5 mg of the active ingredient
More informationDRUG CLASSES BETA-ADRENOCEPTOR ANTAGONISTS (BETA-BLOCKERS)
DRUG CLASSES BETA-ADRENOCEPTOR ANTAGONISTS (BETA-BLOCKERS) Beta-blockers have been widely used in the management of angina, certain tachyarrhythmias and heart failure, as well as in hypertension. Examples
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Atenolol 100mg Film-coated Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each film coated tablet contains Atenolol 100 mg as the
More informationCetirizine Proposed Core Safety Profile
Cetirizine Proposed Core Safety Profile Posology and method of administration Elderly subjects: data do not suggest that the dose needs to be reduced in elderly subjects provided that the renal function
More informationIrbenida H 150mg/12,5mg film-coated tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER Irbenida H 150mg/12,5mg film-coated tablets IRBESARTAN/HYDROCHLOROTHIAZIDE This leaflet is a copy of the Summary of Product Characteristics and Patient Information
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Comfora 595 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One film-coated tablet contains: glucosamine sulphate
More informationLACIPIL QUALITATIVE AND QUANTITATIVE COMPOSITION
LACIPIL lacidipine QUALITATIVE AND QUANTITATIVE COMPOSITION Lacidipine, 2 mg - round shaped white engraved on one face. Lacidipine, 4 mg - oval white with break line on both faces. Lacidipine, 6 mg - oval
More informationScientific conclusions
Annex II Scientific conclusions and grounds for amendment of the summary of product characteristics, labelling and package leaflet presented by the European Medicines Agency 18 Scientific conclusions Overall
More informationPRODUCT CIRCULAR. Tablets COZAAR (losartan potassium) I. THERAPEUTIC CLASS II. INDICATIONS III. DOSAGE AND ADMINISTRATION PAK-CZR-T
PRODUCT CIRCULAR Tablets I. THERAPEUTIC CLASS, the first of a new class of agents for the treatment of hypertension, is an angiotensin II receptor (type AT 1 ) antagonist. also provides a reduction in
More informationTILAZEM. Diltiazem hydrochloride 240 mg
Tilazem Capsules Page 1 of 9 TILAZEM Diltiazem hydrochloride SCHEDULING STATUS: S3 PROPRIETARY NAME (AND DOSAGE FORM): TILAZEM 180 CR (controlled-release capsule) TILAZEM 240 CR (controlled-release capsule)
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Carvetrend mg tablets Carvetrend 6.25 mg tablets Carvetrend 12.5 mg tablets Carvetrend 25 mg tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER Carvetrend 3.125 mg tablets Carvetrend 6.25 mg tablets Carvetrend 12.5 mg tablets Carvetrend 25 mg tablets Carvedilol Read all of this leaflet carefully before
More informationM0BCore Safety Profile
M0BCore Safety Profile Active substance: Aciclovir Pharmaceutical form(s)/strength: Tablets 200, 400 or 800 mg Dispersible tablets 200, 400 or 800 mg Oral suspensions 200 mg or 400 mg per 5 ml. Freeze
More informationElements for a public summary
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology High blood pressure, also known as hypertension, occurs in a large percentage of the adult population. Primary (essential) hypertension
More informationINDERAL LA / INDERAL LA 80 ASTRAZENECA
10-14 Presentation Inderal LA and Inderal LA 80 are presented as capsules containing 160 mg and 80 mg respectively of Propranolol Hydrochloride Ph.Eur. in a controlled release formulation. Indications
More informationCore Safety Profile. Pharmaceutical form(s)/strength: Prolonged release tablets, 4 mg and 8 mg (GITS) Date of FAR:
Core Safety Profile Active substance: Doxazosin Pharmaceutical form(s)/strength: Prolonged release tablets, 4 mg and 8 mg (GITS) P - RMS: DK/H/PSUR/0004/002 Date of FAR: 12.12.2011 4.3 Contraindications
More information2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Lacidipine 2 mg Film-Coated Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 2 mg lacidipine. Excipient with known
More informationSalapin: Salbutamol BP 2mg as sulphate in each 5mL of a raspberry cola flavoured, sugar free syrup.
Salapin Salbutamol Syrup 2mg/5mL Qualitative and quantitative composition Salapin: Salbutamol BP 2mg as sulphate in each 5mL of a raspberry cola flavoured, sugar free syrup. Clinical particulars Therapeutic
More informationM0BCore Safety Profile. Pharmaceutical form(s)/strength: several forms and strength DE/H/PSUR/0039/001 Date of FAR:
M0BCore Safety Profile Active substance: Pantoprazole Pharmaceutical form(s)/strength: several forms and strength P-RMS: DE/H/PSUR/0039/001 Date of FAR: 05.12.2013 Annex I : CSP 4.3 Contraindications Hypersensitivity
More informationPackage leaflet: Information for the patient. VEPROL Film coated tablets 40 mg or 80 mg (Verapamil hydrochloride)
Package leaflet: Information for the patient VEPROL Film coated tablets 40 mg or 80 mg (Verapamil hydrochloride) Read this leaflet carefully before you start taking this medicine. - Keep this leaflet.
More informationBRICANYL INJECTION. terbutaline sulfate PRODUCT INFORMATION
BRICANYL INJECTION terbutaline sulfate PRODUCT INFORMATION NAME OF THE MEDICINE Terbutaline sulfate, 2-(tert-butylamino)-1-(3,5-dihydroxyphenyl) ethanol sulfate, a sympathomimetic bronchodilator with a
More informationCore Safety Profile. Pharmaceutical form(s)/strength: Capsules, 0.5 mg AT/H/PSUR/0028/001 Date of FAR:
Core Safety Profile Active substance: Anagrelide hydrochloride Pharmaceutical form(s)/strength: Capsules, 0.5 mg P-RMS: AT/H/PSUR/0028/001 Date of FAR: 02.08.2010 4.3 Contraindications Hypersensitivity
More informationSUMMARY OF PRODUCT CHARACTERISTICS. For the full list of excipients, see section 6.1.
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Atenolol 25mg Tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains Atenolol 25mg. For the full list of excipients,
More informationSUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT TRANSISOFT 8.5 g powder for oral solution in sachet 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each sachet contains 8.5 g of macrogol
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Atenolol 50mg Film-coated Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each film coated tablet contains Atenolol EP 50mg Excipients
More information2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Summary of Product Characteristics 1. NAME OF THE MEDICINAL PRODUCT {To be completed nationally} 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 mg tablets: each tablet contains 1 mg granisetron (as hydrochloride).
More informationP-RMS: IE/H/PSUR/0014/002
Core Safety Profile Active substance: Nitroglycerin Pharmaceutical form(s)/strength: Transdermal patch 25mg, 50mg, 75mg (corresponding to 5, 10 and 15mg per 24 hours respectively P-RMS: IE/H/PSUR/0014/002
More informationLOSARTAN + HYDROCHLOROTHIAZIDE HYZAAR /HYZAAR DS
PRODUCT CIRCULAR WPC-HYZ-T-092007 THERAPEUTIC CLASS LOSARTAN + HYDROCHLOROTHIAZIDE HYZAAR /HYZAAR DS Film-Coated Tablet Antihypertensive LOSARTAN + HYDROCHLOROTHIAZIDE (HYZAAR) is the first combination
More information2. What you need to know before you take Bisoprolol Tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER Bisoprolol 2.5 mg Film-coated Tablet Bisoprolol 5 mg Film-coated Tablet Bisoprolol 10 mg Film-coated Tablet Bisoprolol fumarate Read all of this leaflet carefully
More informationPackage Insert. WARNING: Do not take this medicine if you have a history of wheezing or asthma
Package Insert Neodipine M WARNING: Do not take this medicine if you have a history of wheezing or asthma Product Summary 1. Name of the medicinal product Neodipine M 2. Qualitative and quantitative composition
More informationNEW ZEALAND DATA SHEET
1. PRODUCT NAME Sudomyl, Tablet, 60 mg 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Name and strength of the active substance Pseudoephedrine Hydrochloride 60mg Excipient(s) with known effect For the full
More informationPRODUCT INFORMATION INSIG
PRODUCT INFORMATION INSIG NAME OF THE MEDICINE INSIG (Indapamide) DESCRIPTION Chemical name: Indapamide hemihydrate in 4-chloro-N(2-methyl-1-indolinyl)-3-sulfamoyl benzamide hemihydrate. Indapamide is
More informationOXIS TURBUHALER 4.5 µg/dose and 9 µg/dose ASTRAZENECA
10-14 OXIS TURBUHALER 4.5 µg/dose and 9 µg/dose ASTRAZENECA formoterol fumarate dihydrate Inhalation powder Composition Each delivered dose (i.e. the dose leaving the mouthpiece) from Oxis Turbuhaler contains
More informationAnnex I: Proposed Core Safety Profile (CSP) 4.3 Contraindications
Annex I: Proposed Core Safety Profile (CSP) 4.3 Contraindications Hypersensitivity to cefuroxime or to any of the excipients listed in section 6.1. Patients with known hypersensitivity to cephalosporin
More informationINDERAL 10 mg, 40 mg, 80 mg Tablet ASTRAZENECA
10-14 Presentation Tablets containing 10 mg, 40 mg or 80 mg Propranolol Hydrochloride Ph. Eur. Injection for intravenous use containing Propranolol Hydrochloride Ph. Eur. 1 mg per 1 ml, presented in glass
More informationM0BCore Safety Profile. Active substance: Bromazepam Pharmaceutical form(s)/strength: Tablets 6 mg FR/H/PSUR/0066/001 Date of FAR:
M0BCore Safety Profile Active substance: Bromazepam Pharmaceutical form(s)/strength: Tablets 6 mg P-RMS: FR/H/PSUR/0066/001 Date of FAR: 26.11.2013 4.3 Contraindications Bromazepam must not be administered
More information0BCore Safety Profile
0BCore Safety Profile Active substance: Somatropin Pharmaceutical form(s)/strength: Powder and solvent for solution for injection, 4mg/ml, 5 mg/ml and 10 mg/ml P-RMS: FR/H/PSUR/0059/001 Date of FAR: 25.02.2013
More informationAmlodipine plus Lisinopril Tablets AMLOPRES-L
Amlodipine plus Lisinopril Tablets AMLOPRES-L COMPOSITION AMLOPRES-L Each uncoated tablet contains: Amlodipine besylate equivalent to Amlodipine 5 mg and Lisinopril USP equivalent to Lisinopril (anhydrous)
More information0BCore Safety Profile. Pharmaceutical form(s)/strength: Losec MUPS tablets 10, 20 mg (OTC) NL/H/PSUR/0058/001 Date of FAR:
0BCore Safety Profile Active substance: Omeprazole Pharmaceutical form(s)/strength: Losec MUPS tablets 10, 20 mg (OTC) P-RMS: NL/H/PSUR/0058/001 Date of FAR: 13.06.2013 4.2 Posology and method of administration
More informationPUBLIC SUMMARY OF RISK MANAGEMENT PLAN (RMP) CANDESARTAN/HYDROCHLOROTHIAZIDE ORION 8 MG/12.5 MG, 16 MG/12.5 MG, 32 MG/12.5 MG, 32 MG/25 MG ORION
PUBLIC SUMMARY OF RISK MANAGEMENT PLAN (RMP) CANDESARTAN/HYDROCHLOROTHIAZIDE ORION 8 MG/12.5 MG, 16 MG/12.5 MG, 32 MG/12.5 MG, 32 MG/25 MG ORION CORPORATION DATE: 17-04-2015, VERSION 2 VI.2 Elements for
More information1. NAME OF THE MEDICINAL PRODUCT. Vicks Sinex, 0.5 mg/ml, nasal spray solution 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
1. NAME OF THE MEDICINAL PRODUCT Vicks Sinex, 0.5 mg/ml, nasal spray solution 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Oxymetazoline hydrochloride 0.5 mg/ml 1 spray (50 l) contains approximately 25
More informationMETFORMIN HYDROCHLORIDE PROLONGED RELEASE TABLETS IP
For 0 the use only of a Registered Medical Practitioner or hospital or a laboratory This package insert is continually updated: Please read carefully before using a new pack METFORMIN HYDROCHLORIDE PROLONGED
More informationP-RMS: LT/H/PSUR/0004/001
Core Safety Profile Active substance: Dalteparine Pharmaceutical form(s)/strength: Solution for injection, 2500 I.U./0.2ml, 2500 I.U./ml, 5000 I.U./0.2ml, 7500 I.U./0.3ml, 7500 I.U./0.75ml, 10000 I.U./0.4ml,
More informationVersie: maart 2017 SUMMARY OF PRODUCT CHARACTERISTICS. Page 1 of 17
SUMMARY OF PRODUCT CHARACTERISTICS Page 1 of 17 1. NAME OF THE MEDICINAL PRODUCT Bisoprololfumaraat/Hydrochloorthiazide Mylan 2,5/6,25 mg, filmomhulde tabletten Bisoprololfumaraat/Hydrochloorthiazide Mylan
More informationCore Safety Profile. Pharmaceutical form(s)/strength: Dry Powder Inhaler, Nebuliser Suspension, pressurised Metered Dose Inhaler (pmdi)
Core Safety Profile Active substance: Budesonide Pharmaceutical form(s)/strength: Dry Powder Inhaler, Nebuliser Suspension, pressurised Metered Dose Inhaler (pmdi) P - RMS: DK/H/PSUR/0041/001 Date of FAR:
More informationPRODUCT INFORMATION H N O * O
PRODUCT INFORMATION BISOPROLOL PFIZER (bisoprolol fumarate) NAME OF THE MEDICINE The name of the medicine is bisoprolol fumarate. H 3 C OH CH 3 O * O O H N CH 3 CH 3 2. HOOC COOH Chemical name: (RS)-1-[4-[[2-(1-methylethoxy)ethoxy]
More informationEuropean PSUR Work Sharing Project CORE SAFETY PROFILE. Lendormin, 0.25mg, tablets Brotizolam
European PSUR Work Sharing Project CORE SAFETY PROFILE Lendormin, 0.25mg, tablets Brotizolam 4.2 Posology and method of administration Unless otherwise prescribed by the physician, the following dosages
More informationSANDOMIGRAN (pizotifen malate)
SANDOMIGRAN (pizotifen malate) S N CH 3 Pizotifen. COOH CH OH CH 2 COOH MALATE DESCRIPTION Pizotifen is a cycloheptathiophene derivative structurally related to cyproheptadine and the tricyclic antidepressants.
More informationPharmaceutical form(s)/strength: 50, 100, 200, 400 mg tablets P-RMS:
0BCore Safety Profile Active substance: Amisulpride Pharmaceutical form(s)/strength: 50, 100, 200, 400 mg tablets P-RMS: IE/H/PSUR/0017/002 Date of FAR: 28.11.2012 Core Safety Profile [amisulpride] Formulations:
More informationPRODUCT INFORMATION. SUDAFED Sinus 12 Hour Relief Tablets
PRODUCT INFORMATION SUDAFED Sinus 12 Hour Relief Tablets NAME OF THE MEDICINE Pseudoephedrine Hydrochloride CAS 2 Registry Number: 345-78-8 DESCRIPTION SUDAFED Sinus 12 Hour Relief prolonged-release tablets
More informationSUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Atenolol 100mg Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains Atenolol 100mg. For excipients, see section 6.1
More informationGlucophage XR is contra-indicated during breast-feeding.
Name GLUCOPHAGE XR 1000 mg Prolonged release tablets Active ingredient Metformin hydrochloride Composition Each Glucophage XR 1000 mg prolonged release tablet contains as active ingredient 1000 mg metformin
More informationBETAGAN Allergan Levobunolol HCl Glaucoma Therapy
BETAGAN Allergan Levobunolol HCl Glaucoma Therapy Action And Clinical Pharmacology: Levobunolol is a noncardioselective beta- adrenoceptor antagonist, equipotent at both beta1 and beta2 receptors. Levobunolol
More informationCore Safety Profile. Pharmaceutical form(s)/strength: Tablets 5 mg and 10 mg BE/H/PSUR/0002/002 Date of FAR:
Core Safety Profile Active substance: Clotiazepam Pharmaceutical form(s)/strength: Tablets 5 mg and 10 mg P-RMS: BE/H/PSUR/0002/002 Date of FAR: 16.06.2011 4.3 Contraindications is contraindicated
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Colecalciferol Meda 800 IU tablet 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains colecalciferol (vitamin D 3 ) 800 IU
More informationMabThera. SC. The wait is over. MabThera delivered in just 5 minutes. SC= subcutaneous injection
MabThera SC. The wait is over. MabThera delivered in just 5 minutes Abbreviated Prescribing Information MabThera 1400 mg solution for subcutaneous (SC) injection (Rituximab) Indications: Indicated in adults
More informationazilsartan medoxomil
azilsartan medoxomil edarbi 40mg Tablet 80mg Tablet ANTIHYPERTENSIVE Angiotensin II Receptor Antagonist FORMULATION: Each tablet contains 40mg Azilsartan medoxomil (as potassium) Each tablet contains 80mg
More informationCore Safety Profile. Pharmaceutical form(s)/strength: Tablets 5 mg and 20 mg. Date of FAR:
Core Safety Profile Active substance: Lisinopril Pharmaceutical form(s)/strength: Tablets 5 mg and 20 mg P - RMS: PT/H/PSUR/014/01 Date of FAR: 20.07.2011 4.3 Contraindications Hypersensitivity to lisinopril,
More information0BCore Safety Profile. Pharmaceutical form(s)/strength: Gastro-resistant capsules (10, 20, 40 mg) NL/H/PSUR/0058/001 Date of FAR:
0BCore Safety Profile Active substance: Omeprazole Pharmaceutical form(s)/strength: Gastro-resistant capsules (10, 20, 40 mg) P-RMS: NL/H/PSUR/0058/001 Date of FAR: 10.04.2013 CSP Drug Substance Omeprazole
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Cyklonova 500 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Tranexamic acid 500 mg. For the full list of excipients,
More informationPRESCRIBING INFORMATION (PI)
PRESCRIBING INFORMATION (PI) BYDUREON (exenatide) 2MG POWDER AND SOLVENT FOR PROLONGED-RELEASE SUSPENSION FOR INJECTION BYETTA (exenatide) 5 MICROGRAMS AND 10 MICROGRAMS SOLUTION FOR INJECTION, PREFILLED
More informationCONTRAINDICATIONS: Hypersensitivity to the active substance or to any of the excipients
Galvus PRESENTATION: Each tablet contains 50 mg of Vildagliptin INDICATIONS: For the treatment of type 2 diabetes mellitus in adults: i) As monotherapy in patients inadequately controlled by diet and exercise
More informationPRODUCT INFORMATION. Sudafed* Sinus + Anti-inflammatory Pain Relief Caplets
PRODUCT INFORMATION Sudafed* Sinus + Anti-inflammatory Pain Relief Caplets Product description Sudafed* Sinus + Anti-inflammatory Pain Relief caplets contain pseudoephedrine hydrochloride 30 mg and ibuprofen
More informationDaiichi Sankyo s U.S. Products Liability Litigation Settlement Program Moves Forward; More than 97 Percent of Eligible Litigants and Claimants Opt In
Daiichi Sankyo s U.S. Products Liability Litigation Settlement Program Moves Forward; More than 97 Percent of Eligible Litigants and Claimants Opt In Tokyo, Japan and Basking Ridge, NJ June 6, 2018 Daiichi
More informationProduktinformationen för Bisoprolol Merck 2,5 mg, 7,5 mg 10 mg, 1,25 mg, 3,75 mg och 5 mg filmdragerad tablett, MTnr 15238, 15239, 15240, 15380,
Produktinformationen för Bisoprolol Merck 2,5 mg, 7,5 mg 10 mg, 1,25 mg, 3,75 mg och 5 mg filmdragerad tablett, MTnr 15238, 15239, 15240, 15380, 15381, 15382, gäller vid det tillfälle då läkemedlet godkändes.
More informationZESTORETIC 20 mg Tablet ASTRAZENECA
10-14 ZESTORETIC 20 mg Tablet ASTRAZENECA Lisinopril dihydrate hydrochlorothiazide Tablets Composition Each tablet contains lisinopril dihydrate (equivalent to 20 mg anhydrous lisinopril) and 12.5 mg hydrochlorothiazide
More informationMetformin Hydrochloride
Metformin Hydrochloride 500 mg, 850 mg, 500 mg LA and 750 mg LA Tablet Description Informet is a preparation of metformin hydrochloride that belongs to a biguanide class of oral antidiabetic drugs. Metformin
More informationVENTOLIN RESPIRATOR SOLUTION
VENTOLIN RESPIRATOR SOLUTION Salbutamol QUALITATIVE AND QUANTITATIVE COMPOSITION VENTOLIN Respirator Solution contains 5mg salbutamol, as sulphate, per ml of solution and is supplied in 10 ml bottles.
More informationNEW ZEALAND DATA SHEET SEREVENT Accuhaler
NEW ZEALAND DATA SHEET SEREVENT Accuhaler Salmeterol xinafoate (50 mcg per inhalation) Presentation SEREVENT Accuhaler is a moulded plastic device containing a foil strip with 60 regularly placed blisters
More informationShared Care Guideline Metolazone for fluid management in CKD (Adults)
Shared Care Guideline Metolazone for fluid management in CKD (Adults) It is vital for safe and appropriate patient care that there is a clear understanding of where clinical and prescribing responsibility
More informationEach film-coated tablet contains metformin hydrochloride 850 mg corresponding to metformin base 662,9 mg
SUMMARY OF THE PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Metformin Actavis 850 mg film-coated tablet. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains metformin
More informationAgreed Core Safety Profile for Budesonide nasal spray suspension and Budesonide nasal powder
CSP Drug Budesonide Substance Date 13 Oct 2011 rev 11Nov Supersedes 18 Aug 2011 Agreed Core Safety Profile for DK/H/PSUR/0041/001 TABLE OF CONTENTS PAGE TITLE PAGE... 1 TABLE OF CONTENTS... 2 Introduction...
More informationNEW ZEALAND DATA SHEET
NEW ZEALAND DATA SHEET TRANDATE Injection labetalol hydrochloride injection 5 mg/ml Pharmaceutical Form Solution for injection. Qualitative and Quantitative Composition TRANDATE Injection: 20 ml glass
More informationAntihypertensive drugs SUMMARY Made by: Lama Shatat
Antihypertensive drugs SUMMARY Made by: Lama Shatat Diuretic Thiazide diuretics The loop diuretics Potassium-sparing Diuretics *Hydrochlorothiazide *Chlorthalidone *Furosemide *Torsemide *Bumetanide Aldosterone
More informationCORE SAFETY PROFILE OXYCODONE HYDROCHLORIDE NL/H/PSUR/0054/ January 2013
CORE SAFETY PROFILE OXYCODONE HYDROCHLORIDE NL/H/PSUR/0054/001 16 January 2013 1 4.2 Posology and method of administration (safety aspects only) Posology Elderly patients For oral preparations A dose adjustment
More informationPackage leaflet: Information for the patient. Tenoretic 100 mg/25 mg film coated tablets. atenolol 100 mg, chlortalidone 25 mg
Package leaflet: Information for the patient Tenoretic 100 mg/25 mg film coated tablets atenolol 100 mg, chlortalidone 25 mg Read all of this leaflet carefully before you start taking this medicine because
More informationBLOCADRIL. Composition Blocadril 10 Tablets Each tablet contains Propranolol hydrochloride 10 mg.
BLOCADRIL Composition Blocadril 10 Tablets Each tablet contains Propranolol hydrochloride 10 mg. Tablets Blocadril 40 Tablets Each tablet contains Propranolol hydrochloride 40 mg. Action Propranolol is
More information